Merlin Biosciences, the UK biotechnology venture capital firm, has raised €125m ($123m) in the first round of fundraising for its new fund, with €30m from WestLB, its cornerstone investor from its past two funds.

Fundraising conditions have been difficult for the past year, as private equity firms have suffered from falling valuations and investors have lost confidence in the asset class.